All In Biotech

Drug Trial Radar · NCT06391710

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 203 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

203

Actual

Start

May 6, 2024

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Sponsor type
Industry
First posted
Apr 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with preserved ejection fraction. A total of 200 obese subjects with heart failure with preserved ejection fraction would be enrolled. Eligible subjects were randomly assigned to either HRS9531 group or placebo group and were treated with HRS9531 injection or placebo, respectively, for 52 weeks.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • HRS9531Drug

    subcutaneous

  • PlaceboDrug

    subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary scoreTime frame: From baseline (week 0) to week 36
  2. Change in body weightTime frame: From baseline (week 0) to week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.